Correlates of physical activity in adults with spondyloarthritis and rheumatoid arthritis: a systematic review
- Open Access
- 08.06.2022
- Systematic Review
Abstract
Introduction
Methods
Search strategy
Example search strategy for PubMed (inc. Medline)
Selection criteria
Screening and data extraction
Methodological quality
Data synthesis and coding
Results
Study selection, characteristics and quality
Citations | Design | Participants (n) | Age (years) | Sex (F) | PA measure | Location | Methodological Quality |
|---|---|---|---|---|---|---|---|
Byram et al. [33] | Cross-sectional | RA (165) | 54 | 69% | Customized interview / 2011 Compendium of PA | USA | Fair |
Conigliaro et al. [34] | Cohort / case–control | RA (30) | 56.07 ± 11.7 | 25 | IPAQ | Italy | Poor |
Demmelmaier et al. [35] | Longitudinal | RA (2752) | 60 ± 11 | 2,003 | IPAQ-SF (plus ESAI) | Sweden | Good |
Demmelmaier et al. [36] | Cross-sectional | RA (3152) | 62 (IQR 54–68) | 2,309 | IPAQ-SF (plus ESAI) | Sweden | Good |
Demmelmaier et al. [37] | Longitudinal | RA (2569) | 60 ± 11 | 1,875 | IPAQ-SF (plus ESAI) | Sweden | Good |
Ehrlich-Jones et al. [38] | Cross-sectional | RA (185) | 55 ± 14 | 155 | GT1M Actigraph | USA | Good |
Elkan et al. [39] | Cross-sectional | RA (61) | 60.8 (57.3–64.4) | 61 | IPAQ | Sweden | Fair |
Eurenius et al. [40] | Cross-sectional | RA (298) | 57 (range 19–90) | 225 | Customized self-report | Sweden | Good |
Eurenius et al. [41] | Longitudinal | RA (102) | 57 (range 19–84) | 76 | Customized self-report | Sweden | Good |
Fenton et al. [42] | Cross-sectional | RA (61) | 54.92 ± 12.39 | 67.2.% | GT3X Accelerometer—LPA | UK | Good |
Greene et al. [43] | Cross-sectional | RA (52) | 61 ± 14.5 | 47 | PADS | USA | Good |
Hashimoto et al. [44] | Cross-sectional / case control | RA (20) | 69.4 ± 5.1 | 16 | Actigraph mini-motionlogger, omnidirectional accelerometer | Japan | Good |
Henchoz et al. [45] | Case control / cross-sectional | RA (110) | 53% (40–59) 47% (60–80) | 83 | PAFQ | Switzerland | Good |
Hernández-Hernández et al. [46] | Case-control / cross-sectional / longitudinal | RA (50) | 54.5 ± 7.4 | 44 | IPAQ and RT3 triaxial accelerometer | Spain | Good |
Huffman et al. [47] | Cross-sectional / case–control | RA (51) | 55 (46,64) | 36 | RT3 triaxial accelerometer | USA | Good |
Hugo et al. [48] | Observational | RA (57) | 57.6 ± 10.2 | 73% | Sensewear armband accelerometer | France | Good |
Hurkmans et al. [49] | Multi-centre Cross -sectional | RA (271) | 62 ± 14 | 178 | SQUASH | The Netherlands | Good |
Iverson et al. [50] | Longitudinal | RA (573) | 61 ± 12 | 478 | NHSPAQ II | USA | Good |
Katz et al. [51] | Cross-sectional | RA (158) | 59.2 ± 11.3 | 118 | IPAQ | USA | Good |
Khoja et al. [52] | Cross-sectional | RA (98) | 58 ± 9 | 83 | Sensewear armband (SWA) biaxial accelerometer | USA | Good |
Knittle et al. [53] | Multicentre longitudinal | RA (129) | 60.5 ± 13.6 | 88 | SQUASH | The Netherlands | Fair |
Lee et al. [54] | Cross-sectional | RA (176) | 55 (range 23–86) | 146 | GT1M Actigraph | USA | Fair |
Løppenthin et al. [55] | Cross-sectional | RA (443) | 60 (range 21–88) | 356 | Leisure time physical activity questionnaire & PAS 2 | Denmark | Good |
Lundgren et al. [56] | Cross-sectional | RA (95) | 60 ± 11.9 | 71 | PAI | Sweden | Fair |
Malm et al. [57] | Longitudinal Observational | RA (1387) | 65 ± 15 | 967 | Customized Questionnaire | Sweden | Good |
Mancuso et al. [58] | Longitudinal / case-control | RA (122) | 49 ± 12 | 84% | PAEI | USA | Good |
McKenna, et al., [59] | Cross-sectional | RA (75) | 20% ≤ 49, 20% 50–59, 40% 60–69, 20% 70–79 | 48 | The SeanseWear (Pro 3 Armband (SWA) | Ireland | Good |
Metsios et al. [60] | Cross-sectional | RA (244) | 62.1 (IQR 53.8–69.4) | 174 | IPAQ | UK | Good |
Mochizuki et al. [61] | Cross-sectional | RA (137) | 64 ± 11.6 | 111 | Liferecorder | Japan | Good |
Munsterman et al. [62] | Cross-sectional | RA (60) | 51.8 ± 10.4 | 44 | SQUASH | The Netherlands | Good |
Neuberger et al. [63] | Randomized intervention study | RA (220) | 55.5 (range 40–70) | 82.7% | Self-report: mean mins aerobic exercise / week + mean of other aerobic at T2/3 | USA | Poor |
Piva et al. [64] | Cross-sectional | RA (47) | 56.5 ± 7 | 47 | SenseWear Professional v 6.1 activity monitor | USA | Good |
Prioreschi et al. [65] | Case-control / cross-sectional | RA (50) | 48 ± 13 | 50 | Hip-worn Actical accelerometer | South Africa | Good |
Rongen-van Dartel et al. [66] | Cross-sectional | RA (167) Low: 42 High: 125 | Low: 56.78 ± 11.03, High: 54.79 ± 10.59 | Low: 33, High: 67 | Ankle-worn actometer (Actilog version 4.1) | The Netherlands | Good |
Semanik et al. [67] | Cross-sectional | RA (185) | 70 (range 60–88) | 185 | Yale PA survey | USA | Fair |
Stavropoulos-Kalinoglou et al. [68] | Cross-sectional | RA (150) | F: 59 (IQR 55–64) M: 60 (IQR 59–64) | 102 | IPAQ | UK | Good |
Tierney et al. [69] | Cross-sectional | RA (59) | 60.10 ± 11.27 | 41 | Sensewear armband | Ireland | Good |
Uutela et al. [70] | Cross-sectional | RA (200) | AO: 59 ± 11 No AO: 60 ± 13 | 153 | The FIT Index of Kasari | Finland | Good |
Van den Berg et al. [71] | Observational | RA (252) | 60.5 ± 11.5 | 182 | Customized self-report | The Netherlands | Fair |
Van der Goes et al. [72] | Cross-sectional | RA (165) | Inactive: 57 ± 12 Insufficient: 57 ± 12 Recommended: 60 ± 11 | 71% | SQUASH | The Netherlands | Good |
Citations | Design | Participants (n) | Age | Sex (F) | PA measure | Location | Methodological Quality |
|---|---|---|---|---|---|---|---|
Arends et al. [73] | Cross-sectional / observational | AS (115) | 44.6 ± 12.1 | 44 | IPAQ, SQUASH, and ActiGraph (GT1M) | The Netherlands | Good |
Brodin et al. [74] | Observational | AS (50) | 51.5 (22–76) | 16 | Customized scale | Sweden | Fair |
Brophy et al. [75] | Cohort study | AS (326) | 55 ± 14 | 21% | IPAQ-SF | Wales | Good |
Fabre et al. [76] | Cross-sectional | axSpA (203) | 46 ± 11.6 | 95 | IPAQ | France | Good |
Fongen et al. [77] | Cross-sectional / case control | AS (149) | 49.3 ± 11.1 | 39% | IPAQ | Norway | Good |
Haglund et al. [78] | Cross-sectional | SpA (2167) | 55 ± 14 | 52% | Customized | Sweden | Good |
Meesters et al. [79] | Cross-sectional | SpA (2167) | 55.4 ± 13.9 | 52% | Customized | Sweden | Good |
O’Dwyer et al. [80] | Case-control / cross-sectional | AS (39) | 40 ± 9 | 7 | RT3 triaxial accelerometer | Ireland | Good |
Prince et al. [81] | Multi-centre retrospective observational | AS (52) | 44.8 ± 13.2 | 7 | Customized interview | Australia | Fair |
Van Genderen et al. [82] | Case control / multi-centre cross-sectional | AS (135) | 51 ± 13 | 54 | Actigraph GT3X triaxial accelerometer | The Netherlands | Good |
Van Genderen et al. [83] | Case control / cross-sectional | AS (24) | 48 ± 11 | 10 | Tracmor triaxial accelerometer and Baecke | The Netherlands | Good |
Variable | Positive Relationship | Negative Relationship | No Relationship | Assoc | % Studies |
|---|---|---|---|---|---|
Sociodemographics | |||||
Age | 55 | 35, 36, 40, 45, 49, 50, 53, 54bc, 61c, 64ac, 64ac, 65ac, 67a, 69c, 71, 72 | 33, 35, 39a, 41, 43, 46, 46c, 47c, 57, 59c, 62, 63, 66c | ?? | 16/30 53% |
Gender (female) | 49, 57, 71 | 35, 35, 40, 47c, 55, 59c, 62, 66c, 69c | 33, 36, 41, 43, 54bc, 63, 72 | ?? | 9/19 47% |
Race /Ethnicity (Caucasian) | 50, 54bc | 33, 43, 47c, 67a | 00 | 2/6 33% | |
Educational level | 36, 49, 50, 64ac, 64ac, 71 | 35, 43, 54bc, 63, 67a | ?? | 6/11 55% | |
Employment status | 50, 67a, 69c | 49, 59c, 71 | ? | 3/6 50% | |
Income | 36 | 35, 35, 67a | 0 | 1/4 25% | |
Marital status | 50 | 64ac, 64ac, 67a | 0 | 1/4 25% | |
Living status (children, location) | 36 | 36 | 35, 49, 59c, 71 | 00 | 1/6 17% |
Smoking | 51b, 69c | 33, 39a, 59c, 71 | 00 | 2/6 33% | |
Any use of alcohol | 50 | + | 1/1 100% | ||
Language Comprehension | 36 | 35 | ? | 1/2 50% | |
Physical | |||||
RA Duration | 48c, 48c, 49, 64ac, 65ac, 61c, 72 | 33, 35, 35, 36, 39a, 41, 44c, 45, 46, 46c, 47c, 50, 54bc, 57, 63, 64ac, 66c, 67a | 00 | 7/25 28% | |
Body Mass Index (BMI) / weight / obesity | 61c | 50, 51b, 52c, 52c, 54bc, 65ac, 66c, 68 | 33, 39a, 43, 46, 46c, 47c, 59c, 64ac, 64ac, 69c, 71, 72 | ?? | 8/21 38% |
Comorbidities | 36, 47c, 64ac | 35, 35, 43, 50, 54bc, 63, 64ac | 00 | 3/10 30% | |
Disease activity | 33, 34, 45, 46, 47c, 49, 51b, 52c, 55, 59c, 61c, 69c, 72 | 39c, 40, 41, 44c, 46, 46, 46c, 46c, 46c, 48c, 48c, 50, 52c, 59c, 64ac, 64ac, 65ac, 66c | ?? | 13/31 42% | |
Tender and swollen joint count | 40, 40, 46, 46, 46c, 46c, 57, 57, 63, 66c, 66c | 00 | 0/11 0% | ||
Radiographic joint damage | 72 | 44c, 57 | 0 | 1/3 33% | |
Aerobic fitness | 62 | 40, 63 | 0 | 1/3 33% | |
Strength and muscle function | 51b, 64ac | 40, 41, 63, 64ac | 00 | 2/6 33% | |
Range of motion | 40, 41 | 0 | 0/2 0% | ||
Balance | 64ac | 40, 41, 64ac | 0 | 1/4 25% | |
Function (inability) | 35, 36, 44c, 46, 46c, 47c, 50, 51b, 52c, 52c, 55, 59c, 59c, 61c, 64ac, 64ac, 65ac, 69c | 34, 35, 39a, 40, 41, 42c, 43, 45, 49, 57, 57, 66c | − − | 18/30 60% | |
Gait Speed | 64ac, 64ac | + | 2/2 100% | ||
Pain | 36, 53, 55, 61c | 34, 35, 35, 40, 41, 43, 45, 47c, 54bc, 57, 62, 63, 66c | 00 | 4/17 24% | |
Fatigue | 36, 45, 50, 51b, 55, 55, 55, 55, 58, 63, 66c | 34, 35, 35, 46, 46c, 55, 62 | − − | 11/18 61% | |
Sleep (good/high) | 51b, 59c | 55, 59c, 66c | ? | 2/5 40% | |
Stiffness | 34 | − | 1/1 100% | ||
Other (physical) | |||||
Waist circumference | 70 | 39a, 47c | 0 | 1/3 33% | |
Waist to hip ratio | 33 | 33, 46, 46c | 0 | 1/4 25% | |
Abdominal obesity | 70, 72 | − | 2/2 100% | ||
Fat Mass Index | 39a | 0 | 0/1 0% | ||
Lean/fat mass | 51b | + | 1/1 100% | ||
Body fat | 68 | − | 1/1 100% | ||
Diabetes | 72 | 33, 55, 66c | 0 | 1/4 25% | |
Fat Free Mass Index | 39a | 0 | 0/1 0% | ||
Plasma glucose/insulin | 39a | − | 1/1 100% | ||
Total cholesterol | 33, 39a | 0 | 0/2 0% | ||
Cholesterol efflux capacity | 33 | 0 | 0/1 0% | ||
Low-density lipoprotein | 33, 33, 33, 33, 39a, 52c, 52c | 00 | 0/7 0% | ||
High-density lipoprotein | 33, 33, 33, 33, 39a, 52c | 33, 33, 52c | + + | 6/9 67% | |
Tryglycerides | 52c, 72 | 33, 52c | ? | 2/4 50% | |
Dyslipidaemia | 72 | – | 1/1 100% | ||
Apolipoprotein A1 | 39a | + | 1/1 100% | ||
Apolipoprotein B | 39a | 0 | 0/1 0% | ||
Oxidized LDL | 39a | 0 | 0/1 0% | ||
Antibodies against phosphorylcholine | 39a | + | 1/1 100% | ||
Anti-citrullinated protein antibodies | 34, 72 | 0 | 0/2 0% | ||
Erythrocyte sedimentation rate | 34, 39a, 40, 46, 46c, 47c, 57, 61c, 63, 65ac, 66c | 00 | 0/11 0% | ||
C-reactive protein | 33, 61c | 34, 40, 46, 46c, 51b, 59c, 59c, 63, 65ac, 66c, 72 | 00 | 2/13 15% | |
Matrix metalloproteinase (MMP-3) | 61c | 0 | 0/1 0% | ||
RF positive | 34, 66c | 0 | 0/2 0% | ||
Cardiovascular risk / disease | 46c, 72 | 46, 46, 46c, 66c | 00 | 2/6 33% | |
Hypertension | 33, 72 | − | 2/2 100% | ||
Systolic blood pressure | 52c, 52c | 33 | − | 2/3 67% | |
Diastolic blood pressure | 52c, 52c | 33 | − | 2/3 67% | |
Heart rate | 51b | 33 | ? | 1/2 50% | |
Metabolic syndrome | 46, 72 | 46c | − | 2/3 67% | |
Nutritional complications | 48c, 48c | − | 2/2 100% | ||
Augmentation Index | 33 | − | 1/1 100% | ||
Pulse wave velocity | 33 | 33 | ? | 1/2 50% | |
Agatson Score | 33 | 0 | 0/1 0% | ||
Insulin resistance | 33, 52c, 52c | − | 3/3 100% | ||
RA -related joint surgery | 50 | − | 1/1 100% | ||
COPD | 66c | 0 | 0/1 0% | ||
Haemoglobin | 66c | 0 | 0/1 0% | ||
Psychological | |||||
Exercise beliefs and (outcome) expectations | 36, 36, 38c, 54bc, 63 | 35, 35, 35, 35, 43 | ?? | 5/10 50% | |
Motivation | 38c, 47c, 49, 53, 54bc | 47c | + + | 5/6 83% | |
Subjective Vitality | 42c | + | 1/1 100% | ||
Self-efficacy | 35, 36, 43, 47c, 47c, 50, 53 | 35, 63, 66c | + + | 7/10 70% | |
Depression / anxiety | 42c, 51b | 35, 35, 55, 62, 63, 66c | 00 | 2/8 25% | |
Life worries | 38c | 0 | 0/1 0% | ||
Health perception (good global health / assessment) | 34, 36, 50, 50, 55, 61c | 34, 35, 35, 40, 41, 57, 59c, 59c | ?? | 6/14 43% | |
Fear Avoidance Beliefs | 36, 37 | 35, 35, 56 | ? | 2/5 40% | |
Other (psychological) | |||||
Life beliefs | 63 | 0 | 0/1 0% | ||
Health locus of control | 41, 56 | 0 | 0/2 0% | ||
Pain and impairment relationship | 56 | 0 | 0/1 0% | ||
Health-related quality of life | 50, 53, 53, 65ac | 46, 46, 46c, 46c, 54bc, 65ac | ?? | 4/10 40% | |
Individual SF-36 measures (health status) | 34, 34, 50 | 44c, 44c, 44c, 44c, 44c, 44c, 44c, 44c, 65ac, 65ac, 65ac, 65ac, 65ac, 65ac, 65ac, 65ac, 65ac, 66c, 66c, 66c | 00 | 3/23 13% | |
Arthritis Impact | 34 | 0 | 0/1 0% | ||
Beliefs about causes of fatigue | 66c, 66c | 0 | 0/2 0% | ||
Coping strategies (fatigue) | 66c, 66c, 66c, 66c, 66c, 66c | 00 | 0/6 0% | ||
Fatigue catastrophizing | 66c, 66c, 66c | 0 | 0/3 0% | ||
Social | |||||
Social support | 36, 42c | 35 | 35, 35, 35, 43, 49, 63 | 00 | 2/9 22% |
Other | |||||
Previous levels of PA | 35, 35, 41 | + | 3/3 100% | ||
Medications / biologics | 46, 46c, 72 | 39a, 39a, 39a, 47c, 47c, 47c, 47c, 50, 50, 50, 50, 50, 51b, 66c, 66c, 66c, 66c, 72, 72 | 00 | 3/22 14% | |
Hospital admission /length | 60, 60 | − | 2/2 100% | ||
Goal Achievement | 53 | 0 | 0/1 0% |
Variable | Positive relationship | Negative relationship | No Relationship | Assoc | % Studies |
|---|---|---|---|---|---|
Sociodemographics | |||||
Age | 78, 83 | 78 | 74, 76, 82c, 83c | 00 | 2/7 29% |
Gender (female) | 78 | 78 | 74, 76, 82c, 82c | 00 | 1/6 17% |
Marital status (married) | 74 | 76 | ? | 1/2 50% | |
Employment (employed) | 74, 76 | 0 | 0/2 0% | ||
Educational level | 76, 78, 78 | 0 | 0/3 0% | ||
Raised children under 12 years | 76 | 0 | 0/1 0% | ||
Smoking | 78 | 78 | ? | 1/2 50% | |
Physical | |||||
Comorbidities | 76 | 0 | 0/1 0% | ||
Symptom duration | 74, 76 | 0 | 0/2 0% | ||
Diagnosis duration | 74 | 82c | 82c, 83, 83c | 0 | 1/5 20% |
Peripheral Joint involvement | 74 | 0 | 0/1 0% | ||
Disease activity | 74, 76, 82c | 73, 73, 73, 73, 73c, 75, 77, 78 | 73c, 76, 78, 80c, 80c, 82c, 83, 83c | ?? | 8/19 42% |
Erythrocyte sedimentation rate | 73c | 73, 73 | 0 | 1/3 33% | |
C-reactive protein | 73c | 73, 73, 76 | 0 | 1/4 25% | |
Function (inability) | 74 | 73, 73, 73c, 75, 78, 78, 82c, 83c | 76, 80c, 82c, 83 | − − | 8/13 62% |
Spinal immobility | 74 | 0 | 0/1 0% | ||
Occiput-to-wall distance | 73 | 73, 73c | 0 | 1/3 33% | |
Chest expansion | 73, 73, 73c | 0 | 0/3 0% | ||
Modified Schober test | 73, 73c | 73 | + | 2/3 67% | |
Lateral spinal flexion | 73c | 73, 73 | 0 | 1/3 33% | |
Cervical rotation | 73, 73c | 73 | + | 2/3 67% | |
Radiographic signs | 76 | 0 | 0/1 0% | ||
Axial pain | 76 | 0 | 0/1 0% | ||
Fatigue | 83, 83, 83 | 83, 83, 83c, 83c, 83c, 83c, 83c | 00 | 3/10 30% | |
Psoriatic arthritis subtype | 78 | 78 | ? | 1/2 50% | |
Undifferentiated spondyloarthritis subtype | 78, 78 | 0 | 0/2 0% | ||
Inflammatory bowel disease-related arthritis | 78, 78 | 0 | 0/2 0% | ||
Uveitis | 76 | 0 | 0/1 0% | ||
Psoriasis | 76 | 0 | 0/1 0% | ||
Inflammatory bowel disease | 76 | 0 | 0/1 0% | ||
HLA B27 antigen | 76 | 0 | 0/1 0% | ||
Inflammatory back pain | 76 | 0 | 0/1 0% | ||
Arthritis | 76 | 0 | 0/1 0% | ||
Enthesitis | 76 | 0 | 0/1 0% | ||
Dactylitis | 76 | 0 | 0/1 0% | ||
Surgery due to axSpA | 76 | 0 | 0/1 0% | ||
Body Mass Index (BMI) | 82c | 76, 82c, 83, 83c | 00 | 1/5 20% | |
Aerobic fitness (VO2max) | 80c | + | 1/1 100% | ||
Having ankylosing spondylitis | 81 | − | 1/1 100% | ||
Psychological | |||||
Health perceptions (overall / disease) | 74 | 74, 76, 83, 83c | 00 | 1/5 20% | |
Quality of life | 73, 73, 73c, 78, 78 | 80c | + + | 5/6 83% | |
Motivation | 75, 75, 75 | 75 | 75, 75 | ? | 3/6 50% |
Perception of exercise | 76, 76 | 0 | 0/2 0% | ||
Depression | 79 | 76, 78, 78 | 0 | 1/4 25% | |
Anxiety | 76, 78, 78, 79 | 00 | 0/4 0% | ||
Environmental | |||||
Seasonal variation (summer) | 77 | + | 1/1 100% | ||
Other | |||||
Previous levels of PA | 74 | + | 1/1 100% | ||
Medication / biologics | 81 | 74, 76, 76 | 0 | 1/4 25% | |
Age of anti-TNF therapy | 81 | − | 1/1 100% | ||
Physiotherapy | 76 | 0 | 0/1 0% |